Omega-3 at 40: the cardiovascular and cognitive case for adequate EPA and DHA

Omega 3 at 40: the cardiovascular and cognitive case

The honest answer is that omega-3 fatty acids - specifically EPA and DHA - have more credible human evidence behind them than almost anything else in the supplement space. A 2019 meta-analysis of 13 RCTs found high-dose EPA reduced major cardiovascular events by 18% compared to placebo. The cognitive picture is more nuanced, but DHA in particular has a plausible mechanism and decent supporting data. At 40, both matter more than they did at 25.

What the evidence actually shows

Start with the cardiovascular side, because that's where the largest and most rigorous trials sit. The REDUCE-IT trial - 8,179 participants, median follow-up 4.9 years - found that 4g/day of icosapentaenoic acid (EPA ethyl ester) reduced major adverse cardiovascular events by 25% versus mineral oil placebo (HR 0.75, 95% CI 0.68-0.83, p<0.001) in people with elevated triglycerides already on statins. [Bhatt et al. (2019)]. That's a large effect in a hard-outcomes trial. It's not surrogate data. People didn't just have better lipid panels - they had fewer heart attacks.

The cognitive picture requires more care. A Cochrane review of 28 RCTs found no consistent benefit of omega-3 supplementation on cognitive function in cognitively healthy older adults. [Sydenham et al. (2012)]. That sounds damning, and it would be if the story ended there. But it doesn't. Several of those trials used low doses, short durations, or populations who already had adequate DHA status - which tends to compress effect sizes toward null. The more interesting data comes from populations with low baseline DHA, or from trials specifically targeting early cognitive decline rather than healthy ageing.

In the MIDAS trial - 485 healthy adults aged 55 and older with age-related cognitive decline - 900mg/day of algal DHA for 24 weeks improved episodic memory scores by the equivalent of roughly 3 years' worth of age-related decline compared to placebo. [Yurko-Mauro et al. (2010)]. That's not nothing. The participants weren't demented - they were the kind of people who notice they're forgetting names more than they used to. Which, at 40, starts to feel personally relevant.

What's biologically happening: the mechanism

DHA - docosahexaenoic acid - is the dominant structural fatty acid in the brain. It makes up roughly 30-40% of the fatty acids in the cerebral cortex and is particularly concentrated in synaptic membranes. This matters because membrane fluidity affects how efficiently neurotransmitter receptors function, how readily vesicles fuse and release their contents, and how responsive neurons are to signalling molecules.

As you age, DHA incorporation into neuronal membranes declines - partly because biosynthesis from ALA (the plant-based precursor) is inefficient in humans, converting at roughly 0-4% to EPA and under 0.1% to DHA in most studies. [Burdge & Calder (2005)]. If you're not eating oily fish two or three times a week, your brain is probably not getting what it needs from diet alone.

On the cardiovascular side, the mechanisms are multiple and reasonably well-characterised. EPA and DHA reduce hepatic triglyceride synthesis and secretion, lower VLDL production, and modestly raise HDL. They also reduce platelet aggregation, lower resting heart rate, and have anti-inflammatory effects mediated partly through competition with arachidonic acid for cyclooxygenase enzymes. Resolvins and protectins - lipid mediators derived from EPA and DHA - actively resolve inflammation rather than simply suppressing it. [Serhan et al. (2008)].

At 40, chronic low-grade inflammation is increasingly relevant. It's not dramatic - no fever, no obvious symptoms - but it's associated with accelerating atherosclerosis, declining neuroplasticity, and a creeping deterioration in metabolic function. The fact that omega-3s address this through multiple pathways simultaneously is one reason the clinical data is more compelling than for most single-mechanism interventions.

Why 40 is a meaningful threshold

I'm not being dramatic about the age. There are real biological reasons why the fourth decade matters for this particular conversation.

First, cardiovascular risk accumulates silently. Atherosclerotic plaques begin forming decades before they cause events. A 40-year-old with borderline triglycerides and a sedentary job is already building the substrate for a problem that will manifest at 55 or 60. The window for primary prevention is open now, not later.

Second, the brain starts showing measurable changes in the late 30s and early 40s. Hippocampal volume begins declining around age 40 at roughly 0.5% per year in healthy adults. [Raz et al. (2005)]. Processing speed peaks in the mid-20s. Working memory starts its slow decline around 30. None of this is catastrophic at 40 - but it's the beginning of a trajectory, and DHA status is one of the modifiable factors that influences how steep that trajectory is.

Third, dietary habits calcify. The person you are at 40 - what you eat, how much you move, whether you sleep - is largely who you'll be at 60. Interventions that are easy to sustain matter more than dramatic short-term measures. A daily omega-3 supplement is low friction. The evidence for it is credible. The downside risk is minimal. That combination is rarer than it sounds in this space.

EPA vs DHA: does the distinction matter?

Yes, and it's worth understanding rather than just buying whatever's on the shelf.

EPA appears to dominate the cardiovascular benefit in the high-dose trials. The REDUCE-IT trial used pure EPA. The STRENGTH trial - which used a mixed EPA/DHA formula - failed to show significant cardiovascular benefit, though the comparison was complicated by the corn oil placebo raising LDL. [Nicholls et al. (2020)]. The debate about whether the mineral oil placebo in REDUCE-IT inflated the apparent benefit is ongoing and legitimate, but the directional evidence still points toward EPA for cardiovascular endpoints.

DHA, on the other hand, is the dominant structural fatty acid in the brain. Most of the cognitive research - including the MIDAS trial mentioned above - uses DHA-focused or DHA-dominant formulas. DHA also crosses the blood-brain barrier more readily than EPA. If your primary concern is cognitive function, DHA is the one to prioritise.

In practice, most people aren't choosing between them - they're choosing between doing something and doing nothing. A standard fish oil or algal DHA supplement provides both. But if you're reading labels carefully (and you should - see why supplement labels lie for context on how confusing label reading can get), look for the actual EPA and DHA content listed separately, not just "omega-3s" or "fish oil" as a total.

Algal DHA: the source question

Fish don't make DHA. They accumulate it by eating microalgae. Going directly to the algal source removes the fish entirely - no heavy metal concerns, no fishy aftertaste, and a more sustainable supply chain. The bioavailability of algal DHA appears equivalent to fish oil. A crossover study in 32 healthy adults found that algal DHA and cooked salmon produced comparable increases in plasma DHA concentrations. [Arterburn et al. (2008)].

This matters practically. The Kojo formula uses algal DHA specifically because the purity and sustainability arguments are real, not just marketing. Algal DHA is also the only form with an authorised EU/UK nutrition and health claim for DHA's contribution to normal brain function. That claim requires a minimum of 250mg DHA per day - which is where most of the cognitive trial data clusters for maintenance doses.

If you're interested in how DHA fits alongside other brain-relevant lipids, the piece I wrote on the case for phosphatidylserine: why your brain needs specific fats covers the phospholipid side of the same story. The two are complementary - DHA as structural raw material, phosphatidylserine as the membrane scaffold it integrates into.

What dose does the clinical evidence support?

This depends entirely on what you're trying to address.

For triglyceride reduction, the FDA-approved prescription dose is 4g/day of EPA+DHA combined, or pure EPA (as in REDUCE-IT). At this dose, triglyceride reductions of 20-30% are typical in hypertriglyceridaemic patients. [Skulas-Ray et al. (2011)]. This is a therapeutic dose - more than you'd typically get from a standard supplement.

For cognitive maintenance in healthy adults, the evidence clusters around 250-900mg DHA/day. The MIDAS trial used 900mg algal DHA. Most observational studies associating higher DHA status with slower cognitive decline involve populations consuming 200-500mg/day from combined dietary and supplemental sources.

For general cardiovascular health in people without diagnosed hypertriglyceridaemia, the European Society of Cardiology recommends 1g/day EPA+DHA. Most large-scale prevention trials - including VITAL, which showed a 28% reduction in fatal MI with 1g/day omega-3 in a primary prevention population - used doses in the 840mg-1g range. [Manson et al. (2019)].

The honest summary: 250mg DHA/day is the floor for cognitive maintenance. 1g EPA+DHA/day is a reasonable cardiovascular prevention dose. 4g/day EPA is where the hard cardiovascular outcome data lives, but that's a clinical intervention, not a supplement strategy.

Omega 3 and the rest of the cognitive stack

Omega-3 doesn't exist in isolation. At 40, if you're thinking seriously about cognitive longevity, it sits alongside a small number of other interventions with credible evidence.

Creatine monohydrate is one of them - not for the gym, but for the brain. Creatine supports phosphocreatine resynthesis in neurons, which matters for energy-intensive cognitive tasks. The approved claim is straightforward: creatine increases physical performance in successive bursts of short-term, high-intensity exercise, but the neurological research is growing. Sleep deprivation studies in particular show creatine attenuating cognitive decline under stress.

There's also the question of other nootropic compounds. The lion's mane benefits literature is interesting - the hericenone and erinacine compounds have shown NGF-stimulating activity in cell and animal models, with a small number of human RCTs showing cognitive benefit in older adults. The human data is thinner than for omega-3, and I'd be overstating it to claim equivalence. But it's not nothing either.

The principle I come back to is stacking interventions with independent mechanisms. DHA supports membrane structure. Creatine supports energy metabolism. Lion's mane potentially supports neurotrophin signalling. These aren't redundant - they address different parts of the same problem.

The safety picture

Omega-3 at typical supplement doses is well tolerated. The main practical concern is fishy burps - solved by refrigerating capsules or using algal DHA. At doses above 3g/day, there's a theoretical concern about bleeding time, but a systematic review found no clinically significant effect on bleeding in healthy adults at doses up to 3g/day. [Larsson et al. (2004)].

If you're on anticoagulants - warfarin, rivaroxaban - have a conversation with your GP before starting high-dose omega-3. That's not fear-mongering; it's just appropriate caution for a drug interaction that's theoretically possible, even if the clinical evidence for it is weak.

Environmental contaminants in fish oil are a legitimate concern at scale. Farmed fish oil can concentrate PCBs and dioxins. Molecular distillation removes most of these, and reputable manufacturers publish third-party testing. Algal DHA bypasses this entirely - it's grown in controlled fermentation tanks, not the open ocean.

Frequently asked questions

My honest take

I started taking omega-3 seriously at 38, not because I read a headline but because I spent a few weeks going through the cardiovascular literature properly and came away genuinely persuaded. The REDUCE-IT data is hard to dismiss. The mechanistic picture for DHA in the brain is coherent and well-supported. The risk profile is about as clean as any supplement gets.

What I'm less certain about is whether the cognitive benefits are meaningful for someone who already has decent DHA status from diet. I eat fish probably twice a week. My baseline is probably not terrible. Whether I'm getting a measurable cognitive benefit from supplementing on top of that - I genuinely don't know. The honest answer is that the trials showing benefit tend to be in populations with low baseline DHA or age-related cognitive decline, not in healthy 40-year-olds eating reasonably well.

What I'm more confident about is the cardiovascular case. Triglycerides, inflammation, platelet aggregation - these are real mechanisms with real outcome data. And the intervention is low cost, low risk, and easy to sustain. That combination is unusual enough in preventive health that I think it deserves to be taken seriously.

I'd rather be honest about the limits than oversell it. The cognitive case at 40 is plausible and worth the investment. The cardiovascular case is stronger. Together, they make omega-3 one of the few supplements I take without reservation.